Solenopsin

Solenopsin (10 μM; 24 h) potently inhibits proliferation of human A375 melanoma, human A2058 melanoma, and murine SVR angiosarcoma cells, with activity equivalent to its enantiomer (+)-solenopsin A and greater than cis isomer or long side-chain analogs^[1].
Solenopsin (10-20 μM; 1 h) inhibits PDGF-induced Akt activity and PDK1 activation in membrane rafts of murine embryonic NIH3T3 fibroblast cells, with full inhibition at 20 μM for 1 hour and partial inhibition at 10 μM for 1 hour^[1].
Solenopsin (10 μM; 24 h) upregulates p-Akt ^S473 and p-MAPK 44/42 in human A375 and A2058 melanoma cells, while downregulating these phosphorylated proteins in murine SVR angiosarcoma cells, demonstrating a context-dependent effect based on p53 status^[1].
Solenopsin (10 μM; 24 h) reduces mitochondrial oxygen consumption rate in human UM-SCC1A squamous carcinoma cells^[1].
Solenopsin (10 μM; 18 h) induces mitophagy in human UM-SCC1A squamous carcinoma cells^[1].
Solenopsin (10 μM; 24 h) elevates reactive oxygen species levels by 1.7-2.3 fold in human A375 melanoma and murine SVR angiosarcoma cells^[1].
Solenopsin (10 μM) potently and selectively inhibits purified recombinant Akt1 in an ATP-competitive manner with an IC₅₀ of 5 to 10 μM at 0.1 mM ATP, while only significantly inhibiting one additional kinase (RSK1) out of 28 tested enzymes, and not inhibiting purified PI3K or PDK1^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.